Technological and product-market experience and the success of new product introductions in the pharmaceutical industry

The growth and development of a firm depend on its ability to introduce new products over time. To do this successfully, it requires technological knowledge, the ability to combine knowledge elements into valuable new products, and the complementary assets that facilitate the manufacturing, sales, and distribution of those products. We argue that these all develop as a function of a firm's experience in its technological and product-market domains. Moreover, given the prospect of complementarities among technological and product-market experience, the value of any one type of experience may be enhanced by the presence of another. Therefore, new products will be more successful when a firm possesses the appropriate stocks of technological and product-market experience. We test this idea by analyzing whether pharmaceutical firms' experience in their technological and product-market domains confer early advantages to their new product offerings, and lead to higher initial sales levels. Copyright © 2004 John Wiley & Sons, Ltd.

[1]  Barton A. Weitz,et al.  Brand Introduction Strategies and Competitive Environments , 1990 .

[2]  David J. Teece,et al.  Towards an economic theory of the multiproduct firm , 1982 .

[3]  D Schwartzman.  "Innovation in the Pharmaceutical Industry". , 1978, British medical journal.

[4]  Rita Gunther McGrath,et al.  Real options reasoning and a new look at the R&D investment strategies of pharmaceutical firms , 2004 .

[5]  J. Schumpeter.  The Theory of Economic Development: An Inquiry into Profits, Capital, Credit, Interest, and the Business Cycle , 1934 .

[6]  C. Shapiro.  Premiums for High Quality Products as Returns to Reputations , 1983 .

[7]  S. Winter.  Knowledge and Competence as Strategic Assets , 1987 .

[8]  Atul Nerkar,et al.  Old Is Gold? The Value of Temporal Exploration in the Creation of New Knowledge , 2003, Manag. Sci..

[9]  Nicolaj Siggelkow.  Evolution toward Fit , 2002 .

[10]  Lee Fleming,et al.  Finding the organizational sources of technological breakthroughs: the story of Hewlett‐Packard's thermal ink‐jet , 2002 .

[11]  W. P. Barnett,et al.  An Evolutionary Model of Organizational Performance , 1994 .

[12]  Constance E. Helfat,et al.  Know-how and asset complementarity and dynamic capability accumulation : The case of R&D , 1997 .

[13]  Jan W. Rivkin.  Imitation of Complex Strategies , 2000 .

[14]  Curba Morris Lampert,et al.  Entrepreneurship in the large corporation: a longitudinal study of how established firms create breakthrough inventions , 2001 .

[15]  Constance E. Helfat,et al.  The birth of capabilities: market entry and the importance of pre-history , 2002 .

[16]  W. Souder.  Disharmony between R&D and marketing , 1981 .

[17]  Peter W. Roberts,et al.  Suborganizational Evolution in the U.S. Pharmaceutical Industry , 1999 .

[18]  Cynthia A. Montgomery,et al.  Diversified expansion by large established firms , 1991 .

[19]  O. Sorenson,et al.  Science as a Map in Technological Search , 2000 .

[20]  Daniel A. Levinthal.  Strategic Management and the Exploration of Diversity , 1995 .

[21]  I. Cockburn,et al.  Scale, scope, and spillovers: the determinants of research productivity in drug discovery. , 1996, The Rand journal of economics.

[22]  Daniel A. Levinthal.  Adaptation on rugged landscapes , 1997 .

[23]  I. Cockburn,et al.  Measuring competence?: exploring firm effects in pharmaceutical research , 1994 .

[24]  Joel A. C. Baum,et al.  OPPORTUNITY AND CONSTRAINT: ORGANIZATIONS’ LEARNING FROM THE OPERATING AND COMPETITIVE EXPERIENCE OF INDUSTRIES , 1997 .

[25]  Stefan H. Thomke,et al.  Asset accumulation, interdependence and technological change: evidence from pharmaceutical drug discovery , 2002 .

[26]  Mary Tripsas.  Unraveling The Process Of Creative Destruction: Complementary Assets And Incumbent Survival In The Typesetter Industry , 1997 .

[27]  F. Morton,et al.  Entry decisions in the generic pharmaceutical industry. , 1999, The Rand journal of economics.

[28]  D. Dougherty,et al.  Sustained product innovation in large, mature organizations: Overcoming innovation-to-organization problems. , 1996 .

[29]  O. Sorenson.  Letting the market work for you: an evolutionary perspective on product strategy , 2000 .

[30]  B. Silverman.  Technological Resources and the Direction of Corporate Diversification: Toward an Integration of the Resource-Based View and Transaction Cost Economics , 1998 .

[31]  Joan D. Penner-Hahn,et al.  Firm and environmental influences on the mode and sequence of foreign research and development activities , 1998 .

[32]  M. Trajtenberg.  A Penny for Your Quotes : Patent Citations and the Value of Innovations , 1990 .

[33]  J. R. Moore,et al.  The theory of the growth of the firm twenty-five years after , 1960 .

[34]  F. Rothaermel.  Strategic Management Journal Research Note Incumbent's Advantage through Exploiting Complementary Assets via Interfirm Cooperation , 2022 .

[35]  Daniel A. Levinthal,et al.  ABSORPTIVE CAPACITY: A NEW PERSPECTIVE ON LEARNING AND INNOVATION , 1990 .

[36]  Karel Cool,et al.  Asset stock accumulation and sustainability of competitive advantage , 1989 .

[37]  B. Kogut,et al.  Knowledge of the Firm, Combinative Capabilities, and the Replication of Technology , 1992 .

[38]  Allan Afuah,et al.  Mapping technological capabilities into product markets and competitive advantage: the case of cholesterol drugs , 2002 .

[39]  P. Roberts.  Product innovation, product–market competition and persistent profitability in the U.S. pharmaceutical industry , 1999 .

[40]  Daniel A. Levinthal,et al.  The myopia of learning , 1993 .

[41]  James M. Utterback,et al.  Mastering the Dynamics of Innovation , 1996 .

[42]  D. Teece,et al.  DYNAMIC CAPABILITIES AND STRATEGIC MANAGEMENT , 1997 .

[43]  Joel A. C. Baum,et al.  Survival-enhancing learning in the Manhattan hotel industry , 1998 .

[44]  John McGee,et al.  A LONGITUDINAL STUDY OF THE COMPETITIVE POSITIONS AND ENTRY PATHS OF EUROPEAN FIRMS IN THE U.S. PHARMACEUTICAL MARKET , 1996 .

[45]  Robert W. Ruekert,et al.  Interactions between marketing and R&D departments in implementing different business strategies , 1987 .

[46]  Will Mitchell,et al.  Incumbents' use of pre-entry alliances before expansion into new technical subfields of an industry , 1992 .

[47]  Kim B. Clark,et al.  Architectural Innovation: The Reconfiguration of Existing Product Technologies and the Failure of , 1990 .

[48]  Cynthia A. Montgomery,et al.  Of Diamonds and Rust: A New Look at Resources , 1995 .

[49]  Peter W. Roberts,et al.  Product-line expansion and resource cannibalization , 2005 .

[50]  Samuel B. Graves,et al.  Innovative productivity and returns to scale in the pharmaceutical industry , 1993 .

[51]  B. Silverman.  Technological Resources and the Direction of Corporate Diversification: Toward an Integration of the Resource-Based View and Transaction Cost Economics , 1998 .

[52]  E. Hippel,et al.  Lead users: a source of novel product concepts , 1986 .

[53]  Christopher L. Tucci,et al.  Incumbent Entry into New Market Niches: The Role of Experience and Managerial Choice in the Creation of Dynamic Capabilities , 2002, Manag. Sci..

[54]  Fiona M. Scott Morton.  Barriers to entry, brand advertising, and generic entry in the US pharmaceutical industry , 2000 .

[55]  Daniel A. Levinthal,et al.  Co-Evolution of Capabilities and Industry: The Evolution of Mutual Fund Processing , 1994 .

[56]  A. Nerkar,et al.  Beyond local search: boundary‐spanning, exploration, and impact in the optical disk industry , 2001 .

[57]  Gavin J. Wright.  An evolutionary theory of economic change , 1982 .

[58]  S. Winter,et al.  An evolutionary theory of economic change , 1983 .

[59]  W. Mitchell.  Whether and When? Probability and Timing of Incumbents' Entry into Emerging Industrial Subfields , 1989 .

[60]  R. Nelson.  Why do firms differ, and how does it matter? , 1991 .

[61]  Brian J. Loasby,et al.  The organisation of capabilities , 1998 .

[62]  J. Barney.  Firm Resources and Sustained Competitive Advantage , 1991 .

[63]  Peter Temin,et al.  Technology, Regulation, and Market Structure in the Modern Pharmaceutical Industry , 1979 .

[64]  D. Teece,et al.  The Dynamic Capabilities of Firms: an Introduction , 1994 .

[65]  R. Katila,et al.  Technological acquisitions and the innovation performance of acquiring firms: a longitudinal study , 2001 .

[66]  Constance E. Helfat,et al.  Evolutionary trajectories in petroleum firm R&D , 1994 .

[67]  D. Teece.  Profiting from technological innovation: Implications for integration, collaboration, licensing and public policy , 1993 .

[68]  Charles A. Holloway,et al.  How to integrate work and deepen expertise , 1994 .

[69]  Paul Milgrom,et al.  Complementarities and fit strategy, structure, and organizational change in manufacturing , 1995 .

[70]  R. Katila,et al.  SOMETHING OLD, SOMETHING NEW: A LONGITUDINAL STUDY OF SEARCH BEHAVIOR AND NEW PRODUCT INTRODUCTION , 2002 .

[71]  Raphael Amit,et al.  The Dynamics of Innovative Activity and Competitive Advantage: The Case of Australian Retail Banking, 1981 to 1995 , 2003, Organ. Sci..

[72]  Will Mitchell,et al.  The influence of local search and performance heuristics on new design introduction in a new product market , 1998 .